Alpex Solar TOPCon Cell Line to Start Mid-Sep 2026

What has been commissioned and why it matters

Alpex Solar is moving closer to commercialising its 2.2 GW G12R TOPCon (third generation) solar cell manufacturing facility at Kosi Kotwan in Mathura, Uttar Pradesh. Management has described the commissioning of the line as a key near-term milestone because it strengthens backward integration for its module business. The project is positioned around high-efficiency TOPCon cells, with targeted cell efficiency of up to 26.5%. Alongside efficiency, the company is highlighting competitive costs, which it expects to support margins as cell production ramps up.

The development is also relevant for policy-linked demand because the company has applied to the Ministry of New and Renewable Energy (MNRE) to include the facility in the Approved List of Models and Manufacturers (ALMM) List-II. MNRE has confirmed receipt of the application and is evaluating it under the ministry’s guidelines. For companies selling into government-linked and ALMM-dependent tenders, List-II compliance can influence addressable demand.

Updated commissioning timeline shared by management

In the Q4 and FY26 earnings call, management provided a specific commissioning and invoicing window. Managing Director Ashwani Sehgal said production is slated to commence around September 15, 2026. The company expects the first invoice to be raised around September 19 or 20, 2026. Management also indicated a ramp-up period of roughly 30 days following the start of production.

The plant inauguration was guided to take place around September 10, 2026. Management attributed the shift in timeline to a minor fire incident that caused about a one-month delay. The presentation further linked the delay to supply chain and logistics disruptions affecting imported equipment deliveries amid geopolitical uncertainties.

August guidance versus mid-September start

Separate reporting also stated that Alpex expected commercial production in August 2026 at the 2.2 GW TOPCon G12R facility. In that coverage, the plant was described as having an annual nameplate capacity of 2.2 GW and being completed within 15 months of its announcement.

The more granular dates disclosed in the concall place the production start in mid-September 2026, with first invoicing expected in the second half of September. Taken together, the available information suggests earlier market communication pointed to August, while management’s latest on-call timeline reflects the one-month slippage after the July 21, 2026 fire incident and equipment-related disruptions.

Plant and technology details disclosed so far

Alpex’s investor communication described the TOPCon facility as a 9 lakh sq ft integrated plant. The production line is described as automated, supported by AGVs, and equipped with an advanced LECO laser system. These details are typically presented to indicate throughput, process control, and consistency for next-generation cell manufacturing.

The company has framed the asset as its “most consequential near-term milestone” because the ramp-up directly feeds its downstream module operations. The cell line is based on the G12R wafer size and is positioned as part of the industry shift toward higher-efficiency formats.

How the cells will be used: internal consumption focus

Management has outlined that nearly 100% of the cells are expected to be consumed internally for its 2.4 GW module capacity, which the company says is expanding to 3.6 GW soon. In another management commentary, Alpex said around 80-85% of cell output would be consumed internally, with the balance potentially sold or exchanged for other cell formats required by customers.

This internal-consumption strategy matters because it reduces reliance on externally sourced cells, supports supply predictability, and can improve economics when utilisation rises across modules and cells. It also ties the cell ramp-up tightly to module demand and the company’s ability to run both assets at healthy utilisation.

What Alpex expects to produce in the remainder of FY27

For the remaining six months of the fiscal year, management expects to produce roughly 1 GW of cells. This guidance is linked to the mid-September start and the initial ramp-up period. It provides a concrete near-term operational target, which investors often use to track execution and stabilisation of yields.

Management has also shared a revenue potential view for a full year of operations at 2.2 GW cell capacity. According to the company, the business “should be able to do around ₹4,000 crore of revenue” for the next full year with 2.2 GW of cell capacity.

Capex and funding structure disclosed by management

Alpex has stated capex of about ₹890 crore for the 2.2 GW TOPCon cell facility. It also indicated project debt of around ₹341 crore, and said this debt is not expected to exceed roughly ₹350-360 crore. These figures help frame the balance sheet impact and the financing intensity of scaling into cell manufacturing.

While the article information does not quantify future interest costs or depreciation impact, the capex and debt disclosures make it clear that the cell line is a major investment and that execution and ramp-up will be closely tracked against funding assumptions.

FY26 financial baseline highlighted alongside the expansion

The FY26 baseline shared in the material indicates revenue of around ₹2,200 crore and profit after tax (PAT) of ₹201 crore. The company also cited EBITDA margin of 14.7% and PAT margin of 9%, linking performance to expanding margins.

This FY26 context is important because it provides the operating base from which the company is funding and scaling into cell manufacturing. It also helps explain why management is emphasising cost competitiveness and efficiency gains from TOPCon as the cell facility moves toward commercial operations.

ALMM List-II application and compliance angle

Alpex has announced its application for inclusion of the 2.2 GW TOPCon G12R cell manufacturing unit in ALMM List-II with MNRE. Reporting notes that MNRE has formally acknowledged receipt and the application is under evaluation as per prescribed guidelines.

Management has linked the cell line commissioning to supporting ALMM List-II compliance. For domestic manufacturers, ALMM status can influence eligibility in certain procurement channels. The article information stops at the evaluation stage, with no stated approval date.

Key figures at a glance

Why the commissioning is a market-relevant milestone

The commissioning timeline is important because it shifts Alpex toward deeper vertical integration, with the cell line designed to feed its module operations. The company’s stated intention to consume most output internally ties the economics of the new asset to downstream module utilisation and order flows. The move toward TOPCon cells with targeted efficiency up to 26.5% reflects the broader technology shift in solar manufacturing toward higher-efficiency formats.

At the same time, the one-month delay due to the July 21 fire incident and equipment logistics disruptions highlights typical project risks in capital-intensive manufacturing ramps. Investors are likely to watch for execution indicators implied by the company’s own dates, including the start of production, the first invoice, and stabilisation during the roughly 30-day ramp-up window.

Conclusion

Alpex Solar’s 2.2 GW TOPCon G12R cell line at Kosi Kotwan is set to move from commissioning into commercial activity in mid-September 2026, with first invoicing expected by September 19-20. Management expects roughly 1 GW of cell output in the remaining six months of FY27 and has indicated a potential of around ₹4,000 crore revenue for a full year with 2.2 GW cell capacity. Near-term tracking points remain the ramp-up progress, internal consumption execution against module capacity plans, and MNRE’s evaluation outcome for the ALMM List-II application.